Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Position Cut by Mackenzie Financial Corp

Mackenzie Financial Corp trimmed its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 50.2% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 10,209 shares of the biotechnology company’s stock after selling 10,308 shares during the quarter. Mackenzie Financial Corp’s holdings in Sarepta Therapeutics were worth $984,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Montag A & Associates Inc. acquired a new position in shares of Sarepta Therapeutics during the third quarter valued at $30,000. Cary Street Partners Investment Advisory LLC increased its holdings in shares of Sarepta Therapeutics by 154.0% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 154 shares during the period. Fifth Third Bancorp increased its holdings in shares of Sarepta Therapeutics by 1,215.8% during the fourth quarter. Fifth Third Bancorp now owns 1,000 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 924 shares during the period. Hudson Capital Management LLC acquired a new position in shares of Sarepta Therapeutics during the third quarter valued at $206,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of Sarepta Therapeutics by 96.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 2,397 shares of the biotechnology company’s stock valued at $291,000 after purchasing an additional 1,176 shares during the period. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Trading Up 2.5 %

Shares of SRPT opened at $127.39 on Friday. The business’s 50-day moving average price is $126.22 and its 200 day moving average price is $110.43. The stock has a market capitalization of $11.96 billion, a P/E ratio of -20.82 and a beta of 0.94. Sarepta Therapeutics, Inc. has a 1-year low of $55.25 and a 1-year high of $159.89. The company has a current ratio of 3.95, a quick ratio of 3.45 and a debt-to-equity ratio of 1.32.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported $0.47 EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.50. Sarepta Therapeutics had a negative return on equity of 18.97% and a negative net margin of 43.11%. The firm had revenue of $396.80 million during the quarter, compared to analyst estimates of $387.18 million. During the same period last year, the company posted ($1.24) EPS. The business’s quarterly revenue was up 53.6% compared to the same quarter last year. Analysts expect that Sarepta Therapeutics, Inc. will post 2.13 earnings per share for the current year.

Insider Activity

In other news, insider Bilal Arif sold 2,000 shares of Sarepta Therapeutics stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $128.84, for a total transaction of $257,680.00. Following the completion of the sale, the insider now directly owns 26,836 shares in the company, valued at approximately $3,457,550.24. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, insider Bilal Arif sold 2,000 shares of Sarepta Therapeutics stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $128.84, for a total transaction of $257,680.00. Following the completion of the sale, the insider now directly owns 26,836 shares in the company, valued at approximately $3,457,550.24. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Hans Lennart Rudolf Wigzell sold 15,000 shares of Sarepta Therapeutics stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $123.25, for a total value of $1,848,750.00. Following the sale, the director now owns 22,840 shares of the company’s stock, valued at $2,815,030. The disclosure for this sale can be found here. Insiders sold a total of 22,096 shares of company stock worth $2,739,419 in the last three months. 7.40% of the stock is owned by insiders.

Wall Street Analyst Weigh In

SRPT has been the topic of a number of research analyst reports. Citigroup raised their price target on Sarepta Therapeutics from $160.00 to $172.00 and gave the company a “buy” rating in a report on Thursday, February 29th. BMO Capital Markets initiated coverage on Sarepta Therapeutics in a report on Wednesday, January 31st. They set an “outperform” rating and a $170.00 price target on the stock. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $128.00 target price on shares of Sarepta Therapeutics in a report on Thursday, February 29th. Mizuho lifted their target price on Sarepta Therapeutics from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Wednesday, February 14th. Finally, TheStreet raised Sarepta Therapeutics from a “d” rating to a “c-” rating in a report on Monday, March 4th. Four analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $158.38.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.